Effect of sulphation on the oestrogen agonist activity of the phytoestrogens genistein and daidzein in MCF-7 human breast cancer cells

Journal of Endocrinology

Volumn 197, Issue 3, 2008, Pages 503-515

  Pugazhendhi, D ^a   Watson, K A ^a   Mills, S ^a   Botting, N ^b   Pope, G S ^a   Darbre, P D ^a  

^a UNIVERSITY OF READING   (United Kingdom)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DAIDZEIN; EQUOL; ESTRADIOL; ESTROGEN RECEPTOR; GENISTEIN; TRITIUM;

ARTICLE; BINDING AFFINITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CELL STRAIN MCF 7; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ESTROGEN ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; REPORTER GENE; STRUCTURE ACTIVITY RELATION; SULFATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENISTEIN; HUMANS; ISOFLAVONES; PHYTOESTROGENS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFATES;

EID: 44949199110     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-07-0384     Document Type: Article

References (49)

1. Adlercreutz H & Mazur HW 1997 Phyto-oestrogens and western diseases. Annals of Medicine 29 95-120.
2. Adlercreutz H, van der Wildt J, Kinzel J, Attalla H, Wahala K, Makela T, Hase T & Fotis T 1995 Lignan and isoflavonoid conjugates in human urine. Journal of Steroid Biochemistry and Molecular Biology 52 97-103.
3. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, greene GL, Gustafsson JA & Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 753-758.
4. Byford JR, Shaw LE, Drew MGB, Pope GS, Sauer MJ & Darbre PD 2002 Oestrogenic activity of parabens in MCF7 human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 80 49-60.
5. Carosati E, Sciabola S & Cruciani G 2004 Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field. Journal of Medicinal Chemistry 47 5114-5125.
6. Chen WF, Huang MH, Tzang CH, Yang M & Wong MS 2003 Inhibitory actions of genistein in human breast cancer (MCF7) cells. Biochimica et Biophysica Acta 1638 187-196.
7. 3] isoflavone internal standards. Analytical Biochemistry 309 158-172.
8. Collaborative Computational Project Number 4 1994 The CCP4 Suite: Programs for protein crystallography. Acta Crystallography D50 760-763
9. Daly RJ & Darbre PD 1990 Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Research 50 5868-5875.
10. Dampier K, Hudson EA, Howells LM, Manson MM, Walker RA & Gescher A 2001 Differences between human breast cell lines in susceptibility towards growth inhibition by genistein. British Journal of Cancer 85 618-624.
11. Darbre PD, & Daly RJ 1989 Effects of oestrogen on human breast cancer cells in culture. Proceedings of the Royal Society of Edinburgh 95B 119-132.
12. Darbre P, Yates J, Curtis SA & E ing RJB 1983 Effect of estradiol on human breast cancer cells in culture. Cancer Research 43 349-354.
13. Fairley B, Botting NP & Cassidy A 2003 The synthesis of daidzein sulfates. Tetrahedron 59 5407-5410.
14. Goodford PJ 1985 A Computational procedure for determining energetically favorable binding sites on biologically important macromolecules. Journal of Medicinal Chemistry 28 849-857.
15. Green B & Leake RE 1987 Steroid Hormones: A Practical Approach., Oxford, UK: IRL Press Ltd.
16. Harris RM, Wood DM, Bottomley L, Blagg S, Owen K, Hughes PJ, Waring RH & Kirk CJ 2004 Phytoestrogens are potent inhibitors of estrogen sulfation: implications for breast cancer risk and treatment. Journal of Clinical Endocrinology and Metabolism 89 1779-1787.
17. Hsieh CY, Santell RC, Haslam SZ & Helferich WG 1998 Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) ceds in vitro and in vivo. Cancer Research 58 3833-3838.
18. Hwang CS, Kwak HS, Lim HJ, Lee SH, Kang YS, Choe TB, Hur HG & Han KO 2006 Isoflavone metabolites and their in vitro dual functions: they can act as estrogenic agonist or antagonist depending on the estrogen concentration. Journal of Steroid Biochemistry and Molecular Biology 101 246-253.
19. von Itzstein M, Wa W-Y, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW et al. 1993 Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363 418-423.
20. Jones TA, Bergdoll M & Kjeldgaard M 1990 O: A macromolecular modeling environment. In Crystallographic and Modeling Methods in Molecular Design, pp 189-195. Eds C Bugg & S Ealick. Berlin: Springer-Verlag Press.
21. Kinjo J, Tsuchihashi R, Morito K, Hirose T, Aomori T, Nagao T, Okabe H, Nohare T & Masamune Y 2004 Interactions of phytoestrogens with estrogen receptors α and β (III). Estrogenic activities of soy isoflavone aglycones and their metabolites isolated from human urine. Biological and Pharmaceutical Bulletin 27 185-188.
22. Kirk CJ, Harris RM, Wood DM, Waring RH & Hughes PJ 2001 Do dietary phytoestrogens influence susceptibility to hormone-dependent cancer by disrupting the metabolism of endogenous oestrogens? Biochemical Society Transactions 29 209-216.
23. Luckow B & Schutz G 1987 CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements. Nucleic Acids Research 15 5490.
24. Maggiolini M, Bonofiglio D, Marsico S, Panno ML, Cenni B, Picard D & Ando S 2001 Estrogen receptor a mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Molecular Pharmacology 60 595-602.
25. Makela S, Hyder SM & Stancel GM 1999 Environmental estrogens. In Estrogens and Antiestrogens II, Handbook of Experimental Pharmacology, vol 135/II, pp 613-663. Eds M Oettel & E Schillinger. Berlin: Springer Verlag.
26. Manas ES, Xu ZB, Unwalla RJ & Somers WS 2004 Understanding the selectivity of genistein for human estrogen receptor-β using X-ray crystallography and computational methods. Structure 12 2197-2207.
27. Matsumura A, Ghosh A, Pope GS & Darbre PD 2005 Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 94 431-443.
28. Miller WR 1996 Estrogen and Breast Cancer., London: Chapman and Hall.
29. Oettel M & Schillinger E (ed) 1999 Estrogens and Antiestrogens I, Handbook of Experimental Pharmacology vol 135/I, Springer: Berlin.
30. Osborne CK, Hobbs K & Trent JM 1987 Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Research and Treatment 9 111-121.
31. Pastor M, Cruciani G & Watson KA 1997 A Strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantitative srructure-activity relationship analysis. Journal of Medicinal Chemistry 40 4089-4102.
32. Peterson TG, Ji GP, Kirk M, Coward L, Falany CN & Barnes S 1998 Metabolism of the isoflavones genistein and biochanin A in human breast cancer cell lines. American Journal of Clinical Nutrition 68 1505S-1511S.
33. PyMOL(TM) Incentive Product-Copyright (C) 2006 DeLano Scientific LLC.
34. Rimbach G, Weinberg PD, Pascual-Teresa S, Alonso MG, Ewins BA, Turner R, Minihane AM, Botting N, Fairley B, Matsugo S et al. 2004 Sulfation of genistein alters its antioxidant properties and its effect on platelet aggregation and monocyte and endothelial function. Biochimica et Biophysica Acta 1670 229-237.
35. Sacco JC & James MO 2005 Sulfonation of environmental chemicals and their metabolites in the polar bear (Ursus maritimus). Drug Metabolism and Disposition 33 1341-1348.
36. Sciabola S, Carosati E, Baroni M & Mannhold R 2005 Comparison of ligandbased and structure-based 3D-QSAR approaches: a case study on (aryl-)bridged 2-aminobenzonitriles inhibiting HIV-1 reverse transcriptase. Journal of Medicinal Chemistry 48 3756-3767.
37. Setchell KD, Zimmer-Nechemias L, Cai J & Heubi JE 1997 Exposure of infants to phytoestrogens from soy-based infant formula. Lancet 350 23-27.
38. Shaw LE, Sadler AJ, Pugazhendhi D & Darbre PD 2006 Changes in oestrogen receptor-α and -β during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 99 19-32.
39. Shelnutt SR, Cimino CO, Wiggins PA & Badger TM 2000 Urinary pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein. Cancer Epidemiology, Biomarkers and Prevention 9 413-419.
40. Shelnutt SR, Cimino CO, Wiggins PA, Ronis MJJ & Badger TM 2002 Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. American Journal of Clinical Nutrition 76 588-594.
41. Tanenbaum DM, Wang Y, Williams SP & Sigler PB 1998 Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. PINAS 95 5998-6003.
42. Thomas BF, Zeisel SH, Busby MG, Hill JM, Mitchell RA, Scheffler NM, Brown SS, Bloeden LT, Dix KJ & Jeffcoat AR 2001 Quantitative analysis of the principle soy isoflavones genistein, daidzein and glycitein, and theor primary metabolites in human plasma and urine using reverse-phase high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography. B, Biomedical Sciences and Applications 760 191-205.
43. Totta P, Acconcia F, Virgili F, Cassidy A, Weinberg PD, Rimbach G & Marino M 2005 Daidzein-sulface metabolites affect transcriptional and antiproliferative activites of estrogen receptor-β in cultured human cancer cells. Journal of Nutrition 135 2687-2693.
44. Turner R, Baron T, Wolffram S, Minihane AM, Cassidy A, Rimbach G & Weinberg PD 2004 Effect of circulating forms of soy isoflavones on the oxidation of low density lipoprotein. Free Radical Research 38 209-216.
45. Wang C & Kurzer MS 1997 Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutrition and Cancer 28 236-247.
46. Welshons WV, Murphy CS, Koch R, Calaf G & Jordan VC 1987 Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and phytoestrogen equol. Breast Cancer Research and Treatment 10 169-175.
47. Woods HE (Chairman) 2003 Phytoestrogens and Health., UK: Crown copyright.
48. Zhang Y, Song TT, Cunnick JE, Murphy PA & Hendrich S 1999 Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations. Journal of Nutrition 129 399-405.
49. Zhang Y, Hendrich S & Murphy PA 2003 Glucuronides are the main isoflavone metabolites in women. Journal of Nutrition 133 399-404.